Current Role of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC): Which Patients and Why

Ultima Vez Modificado: 8 de octubre del 2004

Share article


Conference Dates: December 4, 2004
Conference Location: Chicago, IL


Sponsoring Group:

Conference Web Page URL: www.thecbce.com/futureprograms.asp

Topics Covered: Overview of EGFR Small-Molecule TKIs, Update on Recent Clinical Data for Small-Molecule TKIs, Second-Line Options for the Treatment of NSCLC, Clinical Variables of Patient Benefit: Who Should We Be Treating?, EGFR Small-Molecule TKIs and Rash: What Does it Mean?, Somatic Mutations and Response to EGFR Small-Molecule TKIs, Case Studies

Conference Objectives:

Who Should Attend: This activity is designed primarily for medical oncologists and other healthcare professionals interested in the treatment of cancer.

Conference Agenda:

Registration Information: To register for this meeting, please visit the conference website at www.thecbce.com/futureprograms.asp or e-mail info@thecbce.com

Continuing Education: Yes


News
Tied to longer progression-free survival than standard chemo in patients with EGFR mutations

Jun 24, 2010 - Gefitinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor, is more effective than standard chemotherapy in extending life for patients with non-small-cell lung cancer who have epidermal growth factor receptor mutations, according to a study published in the June 24 issue of the New England Journal of Medicine.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información